Nonalcoholic Fatty Liver Disease: A Special Consideration in Transjugular Intrahepatic Portosystemic Shunts?
Sarah Wang, Juan G. Abraldes – 21 December 2020
Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration
Frank A. Anania, Lara Dimick‐Santos, Ruby Mehta, Joseph Toerner, Julie Beitz – 19 December 2020
Establishment of a Cell Culture Model Permissive for Infection by Hepatitis B and C Viruses
Teruhime Otoguro, Tomohisa Tanaka, Hirotake Kasai, Nobuhiro Kobayashi, Atsuya Yamashita, Takasuke Fukuhara, Akihide Ryo, Moto Fukai, Akinobu Taketomi, Yoshiharu Matsuura, Kohji Moriishi – 19 December 2020 – Compared with each monoinfection, coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is well known to increase the risks of developing liver cirrhosis and hepatocellular carcinoma. However, the mechanism by which HBV/HCV coinfection is established in hepatocytes is not well understood.
High‐Fat Diet Modulates Hepatic Amyloid β and Cerebrosterol Metabolism in the Triple Transgenic Mouse Model of Alzheimer’s Disease
Cristina R. Bosoi, Milène Vandal, Marine Tournissac, Manon Leclerc, Hortense Fanet, Patricia L. Mitchell, Mélanie Verreault, Jocelyn Trottier, Jessica Virgili, Cynthia Tremblay, H. Robert Lippman, Jasmohan S. Bajaj, Olivier Barbier, André Marette, Frédéric Calon – 18 December 2020 – Obesity and diabetes are strongly associated not only with fatty liver but also cognitive dysfunction. Moreover, their presence, particularly in midlife, is recognized as a risk factor for Alzheimer’s disease (AD).
A Call for Randomization in Clinical Trials of Liver Machine Perfusion Preservation
Paulo N. Martins, Pierre‐Alain Clavien, Rajiv Jalan, Davide Ghinolfi – 17 December 2020
Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care
Antonio Saviano, Florian Wrensch, Marc G. Ghany, Thomas F. Baumert – 17 December 2020 – Infection with the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel coronavirus that emerged in late 2019, is posing an unprecedented challenge to global health. Coronavirus disease 2019 (COVID‐19), the clinical disease caused by SARS‐CoV‐2, has a variable presentation ranging from asymptomatic infection to life‐threatening acute respiratory distress syndrome and multiorgan failure.
Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function
Tingting Jiang, Francisco J. Sánchez‐Rivera, Yadira M. Soto‐Feliciano, Qiyuan Yang, Chun‐Qing Song, Arjun Bhuatkar, Cole M Haynes, Michael T. Hemann, Wen Xue – 17 December 2020
LiverLearning®: 2020 Webinar: New E/M Requirements are Coming January 1: Will You Be Ready?
On January 1, 2021, the Centers for Medicare & Medicaid Services will be implementing significant changes to the outpatient evaluation and management (E/M) codes (CPT® codes 99202-99215) for new and established patients. The agency revised both the documentation requirements and values. Practices, physicians, and staff must understand these modifications to ensure a successful transition next year. To help prepare, AASLD is holding a webinar to explain these changes, including how to correctly bill and document the revised code set, on December 15 at 3pm ET.
The Stanford Integrated Psychosocial Assessment for Transplant Is Associated With Outcomes Before and After Liver Transplantation
Sasha Deutsch‐Link, Ethan M. Weinberg, Therese Bittermann, Mackenzie McDougal, Aniket Dhariwal, Lauren S. Jones, Robert M. Weinrieb, Arpita G. Banerjee, Senayish Addis, Marina Serper – 15 December 2020 – The Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) is a standardized psychosocial evaluation tool used in liver transplantation (LT) evaluation. We assessed the impact of the SIPAT score and subdomains on transplant waitlisting decisions and post‐LT outcomes including immunosuppression (IS) nonadherence, biopsy‐proven rejection, andmortality/graft failure.
Liver Transplant Recipient, Caregiver, and Provider Perceptions of Cardiovascular Disease and Related Risk Factors After Transplant
Lisa B. VanWagner, Elisa Gordon, Lindsay Adamski, Megan Kosirog, Amna Daud, Daniel J. Finn, Donald M. Lloyd‐Jones, Jane L. Holl – 14 December 2020 – Liver transplant recipients (LTRs) are at high risk for cardiovascular disease (CVD). We sought to characterize LTR, informal caregiver, and health care provider perceptions about CVD care after liver transplantation (LT) to inform the design of solutions to improve care.